Compare NGVC & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NGVC | CSTL |
|---|---|---|
| Founded | 1955 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Chains | Medical Specialities |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 707.5M | 722.8M |
| IPO Year | 2012 | 2019 |
| Metric | NGVC | CSTL |
|---|---|---|
| Price | $30.24 | $33.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | $42.25 | ★ $45.22 |
| AVG Volume (30 Days) | 120.1K | ★ 358.1K |
| Earning Date | 11-19-2026 | 11-02-2026 |
| Dividend Yield | ★ 2.00% | N/A |
| EPS Growth | ★ 36.05 | N/A |
| EPS | ★ 1.54 | N/A |
| Revenue | N/A | ★ $344,229,000.00 |
| Revenue This Year | $2.22 | $8.41 |
| Revenue Next Year | $5.52 | $10.30 |
| P/E Ratio | $19.49 | ★ N/A |
| Revenue Growth | N/A | ★ 3.66 |
| 52 Week Low | $23.47 | $17.72 |
| 52 Week High | $41.07 | $44.28 |
| Indicator | NGVC | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 54.68 | 46.46 |
| Support Level | $29.40 | $31.44 |
| Resistance Level | $31.53 | $34.23 |
| Average True Range (ATR) | 0.75 | 1.79 |
| MACD | -0.06 | -0.42 |
| Stochastic Oscillator | 37.97 | 17.27 |
Natural Grocers by Vitamin Cottage Inc operates natural and organic grocery and dietary supplement stores. It offers the following product categories: natural and organic food, dietary supplements, natural body care, household, pet care products, books, and handouts. The Company has a single reporting segment, natural and organic retail stores, through which business is conducted. The company generates the majority of its revenue from grocery products and dietary supplements, and the rest from other products.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.